Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

Coyle, Joseph T.; Basu, Alo; Benneyworth, Michael; Balu, Darrick; Konopaske, Glenn

doi:10.1007/978-3-642-25758-2_10

Cited by 184Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

Open access

Coyle, Joseph T., Basu, Alo, Benneyworth, Michael, Balu, Darrick, Konopaske, Glenn·2012·Handbook of Experimental Pharmacology

DOI 10.1007/978-3-642-25758-2_10PMC PMC4817347

Open this paper in CoChat — free account

Abstract

Schizophrenia affects approximately 1% of the population and continues to be associated with poor outcome because of the limited efficacy of and noncompliance with existing antipsychotic medications. An alternative hypothesis invoking the excitatory neurotransmitter, glutamate, arose out of clinical observations that NMDA receptor antagonists, the dissociative anesthetics like ketamine, can replicate in normal individuals the full range of symptoms of schizophrenia including psychosis, negative symptoms, and cognitive impairments. Low dose ketamine can also re-create a number of physiologic abnormalities characteristic of schizophrenia. Postmortem studies have revealed abnormalities in endogenous modulators of NMDA receptors in schizophrenia as well as components of a postsynaptic density where NMDA receptors are localized. Gene association studies have revealed several genes that affect NMDA receptor function whose allelic variants are associated with increased risk for schizophrenia including genes encoding D-amino acid oxidase, its modulator G72, dysbindin, and neuregulin. The parvalbumin-positive, fast-firing GABAergic interneurons that provide recurrent inhibition to cortical-limbic pyramidal neurons seem to be most sensitive to NMDA receptor hypofunction. As a consequence, disinhibition of glutamatergic efferents disrupts cortical processing, causing cognitive impairments and negative symptoms, and drives subcortical dopamine release, resulting in psychosis. Drugs designed to correct the cortical-limbic dysregulated glutamatergic neurotransmission show promise for reducing negative and cognitive symptoms of schizophrenia as well as its positive symptoms.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/978-3-642-25758-2_10

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Post-mortem studies of schizophrenia brains revealed lower GRIN1 expression, increases in kynurenate, and reductions in D-serine and D-serine racemase.
“Post-mortem studies of the brain of patients with schizophrenia have revealed lower levels of expression of the obligate NMDAR subunit GRIN1 (glutamate receptor ionotropic, NMDA 1), increases in the expression of the endogenous NMDAR antagonist kynurenate, and a reduction in levels of the NMDAR co-agonist D-serine and the enzyme that catalyses its production, D-serine racemase 10,[16][17][18] .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [10]
Treatment of adult rodents with NMDAR antagonists triggers acute schizophrenia-related behaviours, including deficits in attention/vigilance, learning and memory, and sensory gating.
“As in humans, treatment of adult rodents with NMDAR antagonists triggers acute schizophrenia-related behaviours, including deficits in attention and/ or vigilance, learning and memory and sensory gating, broadly mimicking the symptoms of patients with schizophrenia 10,15,23,24 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [10]
NMDAR antagonism during the first 2 postnatal weeks in rodents induces long-lasting behavioural and cognitive disturbances relevant to the schizophrenia phenotype that extend into adolescence and adulthood.
“In supporting of this notion, NMDAR antagonism during an equivalent period in rodents (first 2 post-natal weeks) induces long-lasting behavioural and cognitive disturbances that are relevant to the schizophrenia phenotype and which extend into adolescence and adulthood 10,27 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · see citing works
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,151 · see citing works
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · see citing works
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · see citing works
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies
BRAFF, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,701 · see citing works
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636 · see citing works
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484 · see citing works
Rare chromosomal deletions and duplications increase risk of schizophrenia
The International Schizophrenia Consortium (2008) · Nature · doi:10.1038/nature07239 · Cited by 1,475 · see citing works
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
Whitfield-Gabrieli, S., Thermenos, H. W., Milanovic, S., Tsuang, M. T., Faraone, S. V., McCarley, R. W., Shenton, M. E., Green, A. I., Nieto-Castanon, A., LaViolette, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809141106 · Cited by 1,435 · see citing works
Requirement for Glycine in Activation of NMDA-Receptors Expressed in Xenopus Oocytes
Kleckner, N. W., & Dingledine, R. J. (1988) · Science · doi:10.1126/science.2841759 · Cited by 1,427 · see citing works
The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399 · see citing works
NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · see citing works
Translating developmental time across mammalian species
Clancy, B., Darlington, R. B., & Finlay, B. L. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00171-3 · Cited by 1,221 · see citing works
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia
Hakak, Y., Walker, J. R., Li, C., Wong, W. H., Davis, K. L., Buxbaum, J. D., Haroutunian, V., & Fienberg, A. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081071198 · Cited by 1,192 · see citing works
Prestimulus Effects on Human Startle Reflex in Normals and Schizophrenics
BRAFF, D. L., Stone, C., Callaway, E., Geyer, M. A., Glick, I. D., & Bali, L. (1978) · Psychophysiology · doi:10.1111/j.1469-8986.1978.tb01390.x · Cited by 1,171 · see citing works
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones, P., Barnes, T., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R., Markwick, A., & Lewis, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,060 · see citing works
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database
Allen, N. C., Bagade, S., McQueen, M. B., Ioannidis, J. P. A., Kavvoura, F. K., Khoury, M. J., Tanzi, R. E., & Bertram, L. (2008) · Nature Genetics · doi:10.1038/ng.171 · Cited by 1,054 · see citing works
Modulation of Neuronal Migration by NMDA Receptors
Komuro, H., & RAKIC, P. T. (1993) · Science · doi:10.1126/science.8096653 · Cited by 1,041 · see citing works
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · see citing works
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,035 · see citing works
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia
Mei, L., & Xiong, W.-C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2392 · Cited by 1,030 · see citing works
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010 · see citing works
Self-citation
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006 · see citing works
Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.
Akbarian, S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160008002 · Cited by 1,002 · see citing works
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921 · see citing works
Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors
Harris, E. W., Ganong, A. H., & Cotman, C. W. (1984) · Brain Research · doi:10.1016/0006-8993(84)90275-0 · Cited by 903 · see citing works
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899 · see citing works
Dopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. M. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880 · see citing works
D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release
Schell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832 · see citing works
Serine racemase: A glial enzyme synthesizing <scp>d</scp> -serine to regulate glutamate- <i>N</i> -methyl- <scp>d</scp> -aspartate neurotransmission
Wolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811 · see citing works
Two Forms of the γ‐Aminobutyric Acid Synthetic Enzyme Glutamate Decarboxylase Have Distinct Intraneuronal Distributions and Cofactor Interactions
Kaufman, D. L., Houser, C. R., & Tobin, A. J. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08211.x · Cited by 789 · see citing works
The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications
Hilmas, C., Pereira, E., Alkondon, M., Rassoulpour, A., Schwarcz, R., & Albuquerque, E. X. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 772 · see citing works
A review of diffusion tensor imaging studies in schizophrenia
Kubicki, M., McCarley, R., Westin, C.-F., Park, H.-J., Maier, S., Kikinis, R., Jolesz, F. A., & Shenton, M. E. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.05.005 · Cited by 769 · see citing works
Impulse activity and the patterning of connections during cns development
Shatz, C. J. (1990) · Neuron · doi:10.1016/0896-6273(90)90333-b · Cited by 766 · see citing works
A decrease of reelin expression as a putative vulnerability factor in schizophrenia
Impagnatiello, F., Guidotti, A. R., Pesold, C., Dwivedi, Y., Caruncho, H. J., Pisu, M. G., Uzunov, D. P., Smalheiser, N. R., Davis, J. M., Pandey, G. N., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15718 · Cited by 753 · see citing works
Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia
Garey, L. J., Ong, W., Patel, T. S., Kanani, M., Davis, A., Mortimer, A. M., Barnes, T., & Hirsch, S. R. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.4.446 · Cited by 719 · see citing works
Schizophrenia, “Just the Facts” What we know in 2008. 2. Epidemiology and etiology
TANDON, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.011 · Cited by 716 · see citing works
Decreased Glutamic Acid Decarboxylase67 Messenger RNA Expression in a Subset of Prefrontal Cortical γ-Aminobutyric Acid Neurons in Subjects With Schizophrenia
Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.237 · Cited by 697 · see citing works
Synaptogenesis in the Prefrontal Cortex of Rhesus Monkeys
Bourgeois, J.-P., Goldman-Rakic, P. S., & Rakic, P. (1994) · Cerebral Cortex · doi:10.1093/cercor/4.1.78 · Cited by 687 · see citing works
Altered Distribution of Nicotinamide-Adenine Dinucleotide Phosphate—Diaphorase Cells in Frontal Lobe of Schizophrenics Implies Disturbances of Cortical Development
Akbarian, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820150007001 · Cited by 679 · see citing works
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y., & Chong, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 676 · see citing works
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674 · see citing works
A Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick, B. W., Buchanan, R. W., Ross, D. E., & Carpenter, W. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.165 · Cited by 651 · see citing works
The Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., BALL, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614 · see citing works
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. W. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604 · see citing works
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590 · see citing works
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585 · see citing works
Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers
Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1139 · Cited by 583 · see citing works
D-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., LANGE, N. D., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 572 · see citing works
Self-citation
Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia
Hahn, C.-G., Wang, H.-Y., Cho, D.-S., Talbot, K., Gur, R. E., Berrettini, W. H., Bakshi, K. P., Kamins, J., Borgmann‐Winter, K. E., Siegel, S. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1418 · Cited by 564 · see citing works
NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury
Salter, M. G., & Fern, R. F. (2005) · Nature · doi:10.1038/nature04301 · Cited by 556 · see citing works
Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia
Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueleret, L., Barry, C., Tanaka, H., Rosa, P. L., et al. (2002) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.182412499 · Cited by 541 · see citing works
Progressive Structural Brain Abnormalities and Their Relationship to Clinical Outcome
Ho, B., Andreasen, N. C., Nopoulos, P., Arndt, S. V., Magnotta, V. A., & Flaum, M. A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.585 · Cited by 536 · see citing works
Purification of serine racemase: biosynthesis of the neuromodulator D-serine.
Wolosker, H., Sheth, K., Takahashi, M., Mothet, J., Brady, R., Ferris, C., & Snyder, S. (1999) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.96.2.721 · Cited by 505 · see citing works
Local circuit neurons immunoreactive for calretinin, calbindin D‐28k or parvalbumin in monkey prefronatal cortex: Distribution and morphology
Condé, F., Lund, J. S., Jacobowitz, D. M., Baimbridge, K. G., & Lewis, D. A. (1994) · The Journal of Comparative Neurology · doi:10.1002/cne.903410109 · Cited by 500 · see citing works
Effects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498 · see citing works
Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene.
Bu, D.-F., Erlander, M. G., Hitz, B. C., Tillakaratne, N. J. K., Kaufman, D. L., Wagner-McPherson, C., Evans, G. A., & Tobin, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.6.2115 · Cited by 493 · see citing works
Treatment-Resistant Schizophrenia - The Role of Clozapine
Meltzer, H. Y. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113338 · Cited by 493 · see citing works
Decreased Serum Levels of D-Serine in Patients With Schizophrenia
Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., 篠田, 直., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.572 · Cited by 489 · see citing works
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.
Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L., & Engberg, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02242-x · Cited by 478 · see citing works
Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., AMBLER, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 476 · see citing works
NMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467 · see citing works
A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia
Zhang, Z. J., & Reynolds, G. P. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00188-8 · Cited by 460 · see citing works
Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia
Hashimoto, T., Bazmi, H. H., Mirnics, K., Wu, Q., Sampson, A. R., & Lewis, D. A. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07081223 · Cited by 457 · see citing works
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. E. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455 · see citing works
Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia
Talbot, K., Eidem, W. L., Tinsley, C. L., Benson, M. A., Thompson, E. W., Smith, R. J., Hahn, C.-G., Siegel, S. J., Trojanowski, J. Q., Gur, R. E., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20425 · Cited by 455 · see citing works
Myelination of Cortical-hippocampal Relays During Late Adolescence
Benes, F. M. (1989) · Schizophrenia Bulletin · doi:10.1093/schbul/15.4.585 · Cited by 448 · see citing works
DTI and MTR abnormalities in schizophrenia: Analysis of white matter integrity
Kubicki, M. R., Park, H., Westin, C., Nestor, P. G., Mulkern, R. V., Maier, S. E., Niznikiewicz, M. A., Connor, E. E., Levitt, J. J., Frumin, M., et al. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.03.026 · Cited by 433 · see citing works
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426 · see citing works
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.
Kegeles, L., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J., Heertum, R. V. V., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 425 · see citing works
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 412 · see citing works
Self-citation
Density of Glutamic Acid Decarboxylase 67 Messenger RNA–ContainingNeurons That Express the N-Methyl-D-AspartateReceptor Subunit NR2A in the Anterior Cingulate Cortex in Schizophreniaand Bipolar Disorder
Woo, T.-U. W., Walsh, J. P., & Benes, F. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.649 · Cited by 411 · see citing works
A subclass of prefrontal γ-aminobutyric acid axon terminals are selectively altered in schizophrenia
Woo, T.-U. W., Whitehead, R. E., Melchitzky, D. S., & Lewis, D. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5341 · Cited by 410 · see citing works
Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408 · see citing works
Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium
Knable, M. B., Barci, B. M., Webster, M. J., Meador‐Woodruff, J. H., & Torrey, Ε. F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001471 · Cited by 407 · see citing works
Development of the prefrontal cortex during adolescence: Insights into vulnerable neural circuits in schizophrenia
Lewis, D. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00277-1 · Cited by 388 · see citing works
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
Heresco‐Levy, U., Javitt, D. C., Ebstein, R. P., Vass, Á., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386 · see citing works
Mutational analysis of the glycine-binding site of the NMDA receptor: Structural similarity with bacterial amino acid-binding proteins
Kuryatov, A. (1994) · Neuron · doi:10.1016/0896-6273(94)90445-6 · Cited by 385 · see citing works
Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins
Beasley, C. L., Zhang, Z. J., Patten, I., & Reynolds, G. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01360-4 · Cited by 374 · see citing works
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia.
Numakawa, T., Yagasaki, Y., Ishimoto, T., Okada, T., Suzuki, T., Iwata, N., Ozaki, N., Taguchi, T., Tatsumi, M., Kamijima, K., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh280 · Cited by 373 · see citing works
Ionotropic Glutamate Receptors and Expression of N-Methyl- d -Aspartate Receptor Subunits in Subregions of Human Hippocampus: Effects of Schizophrenia
Gao, X.-M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1141 · Cited by 371 · see citing works
Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics
Benes, F., Vincent, S. L., Alsterberg, G., Bird, E. D., & SanGiovanni, J. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-03-00924.1992 · Cited by 367 · see citing works
What Happens After the First Episode? A Review of Progressive Brain Changes in Chronically Ill Patients With Schizophrenia
Hulshoff Pol, H. E., & Kahn, R. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm168 · Cited by 364 · see citing works
Endogenous d ‐Serine in Rat Brain: N‐Methyl‐ d ‐Aspartate Receptor‐Related Distribution and Aging
Hashimoto, A., Nishikawa, T., Oka, T., & Takahashi, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03219.x · Cited by 363 · see citing works
Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders
Akbarian, S., & Huang, H. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.04.001 · Cited by 362 · see citing works
Human Dysbindin (DTNBP1) Gene Expression inNormal Brain and in Schizophrenic Prefrontal Cortex and Midbrain
Weickert, C. S., Straub, R. E., McClintock, B., Matsumoto, M., Hashimoto, R., Hyde, T. M., Herman, M. M., Weinberger, D. R., & Kleinman, J. E. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.6.544 · Cited by 352 · see citing works
Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia
Adler, C. M., Malhotra, A. K., Elman, I., Goldberg, T. E., Egan, M. F., Pickar, D., & Breier, A. F. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1646 · Cited by 337 · see citing works
Functional Comparison of d ‐Serine and Glycine in Rodents: The Effect on Cloned NMDA Receptors and the Extracellular Concentration
Matsui, T., Sekiguchi, M., Hashimoto, A., Tomita, U., Nishikawa, T., & Wada, K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65010454.x · Cited by 334 · see citing works
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia
Conn, P. J., Lindsley, C. W., & Jones, C. K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.006 · Cited by 330 · see citing works
A Specific Role for NR2A-Containing NMDA Receptors in the Maintenance of Parvalbumin and GAD67 Immunoreactivity in Cultured Interneurons
Kinney, J. W., Davis, C. N., Tabarean, I., Conti, B., Bartfai, T., & Behrens, M. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4722-05.2006 · Cited by 329 · see citing works
Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor.
Birch, P., Grossman, C., & Hayes, A. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90367-6 · Cited by 324 · see citing works
A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia
Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., DEMIRANDA, J., Wolosker, H., & Agam, G. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.10.010 · Cited by 323 · see citing works
Differential Hippocampal Expression of Glutamic Acid Decarboxylase 65 and 67 Messenger RNA in Bipolar Disorder and Schizophrenia
Heckers, S., Stone, D., Walsh, J., Shick, J., Koul, P., & Benes, F. M. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.521 · Cited by 322 · see citing works
Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells
Pearce, I. A., Cambray-Deakin, M. A., & Burgoyne, R. D. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80525-2 · Cited by 314 · see citing works
Principles of Long-Term Dynamics of Dendritic Spines
Yasumatsu, N., Matsuzaki, M., Miyazaki, T., Noguchi, J., & Kasai, H. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0603-08.2008 · Cited by 314 · see citing works
Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder
Schumacher, J. H., Jamra, R. A., Freudenberg, J., Becker, T., Ohlraun, S., Otte, A., Tullius, M., Kovalenko, S., Bogaert, A. V. D., Maier, W., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001421 · Cited by 312 · see citing works
Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain.
Robinson, M. B., Blakely, R., Couto, R., & Coyle, J. T. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47823-4 · Cited by 306 · see citing works
Self-citation
N‐Acetylaspartylglutamate Selectively Activates mGluR3 Receptors in Transfected Cells
Wróblewska, B., Wroblewski, J. T., Sf, P., Surin, A. M., Sullivan, S. E., & Neale, J. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010174.x · Cited by 299 · see citing works
Reduced Dendritic Spine Density in Auditory Cortex of Subjects with Schizophrenia
Sweet, R. A., Henteleff, R. A., Zhang, W., Sampson, A. R., & Lewis, D. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.67 · Cited by 290 · see citing works
Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K. E., Förster, S., Kelly, M. A., & Montrose, D. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030395 · Cited by 286 · see citing works
Modulation of NMDA receptor function: implications for vertebrate neural development
Scheetz, A. J., & Constantine‐Paton, M. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.10.8050674 · Cited by 285 · see citing works
Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects
Benes, F. M., Vincent, S. L., Marie, A. S., & Khan, Y. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00328-4 · Cited by 274 · see citing works
Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Tsai, G. E., & Lin, P. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269 · see citing works
A Single Dominant Gene Can Account for Eye Tracking Dysfunctions and Schizophrenia in Offspring of Discordant Twins
Holzman, P. S. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800310049006 · Cited by 269 · see citing works
Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients
Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267 · see citing works
Reciprocal Alterations in Pre- and Postsynaptic Inhibitory Markers at Chandelier Cell Inputs to Pyramidal Neurons in Schizophrenia
Volk, D. W. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.10.1063 · Cited by 264 · see citing works
Decreased Somal Size of Deep Layer 3 Pyramidal Neurons in the Prefrontal Cortex of Subjects With Schizophrenia
Pierri, J. N., Volk, C. L. E., Auh, S., Sampson, A., & Lewis, D. A. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.466 · Cited by 257 · see citing works
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia.
Nilsson, L., Linderholm, K., Engberg, G., Paulson, L., Blennow, K., Lindström, L., Nordin, C., Karanti, A., Persson, P., & Erhardt, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.013 · Cited by 257 · see citing works
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
GOFF, D. C., Tsai, G. E., Manoach, D. S., & Coyle, J. T. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243 · see citing works
Self-citation
Impairment of early cortical processing in schizophrenia: An event-related potential confirmation study
Javitt, D. C., Doneshka, P., Zylberman, I., Ritter, W., & Vaughan, H. G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90005-x · Cited by 236 · see citing works
MK‐801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex
Sharp, F. R., Jasper, P., Hall, J., Noble‐Haeusslein, L. J., & Sagar, S. M. (1991) · Annals of Neurology · doi:10.1002/ana.410300609 · Cited by 235 · see citing works
Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia
Wang, C., McInnis, J., Ross-Sanchez, M., Shinnick‐Gallagher, P., Wiley, J. L., & Johnson, K. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00384-0 · Cited by 234 · see citing works
Ionotropic Glutamate Receptor Binding and Subunit mRNA Expression in Thalamic Nuclei in Schizophrenia
Ibrahim, H. M., Hogg, A. J., Healy, D. J., Haroutunian, V. H., Davis, K. L., & Meador‐Woodruff, J. H. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1811 · Cited by 233 · see citing works
GABA Transporter-1 mRNA in the Prefrontal Cortex in Schizophrenia: Decreased Expression in a Subset of Neurons
Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R., & Lewis, D. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.256 · Cited by 221 · see citing works
Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic
Depoortère, R., Dargazanli, G., Estenne‐Bouhtou, G., Coste, A., Lanneau, C., Desvignes, C., Poncelet, M., Héaulme, M., Santucci, V., Decobert, M., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300772 · Cited by 220 · see citing works
Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia
Kristiansen, L. V., Beneyto, M., Haroutunian, V, & Meador-Woodruff, J. H. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001844 · Cited by 220 · see citing works
AN ANALYSIS OF FACTORS INFLUENCING MEASUREMENTS OF DOPAMINE, NORADRENALINE, GLUTAMATEDECARBOXYLASE AND CHOLINE ACETYLASE IN HUMAN POST-MORTEM BRAIN TISSUE
Spokes, E. G. (1979) · Brain · doi:10.1093/brain/102.2.333 · Cited by 216 · see citing works
Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration.
Kim, P. M., Aizawa, H., Kim, P. S., Huang, A. S., Wickramasinghe, S. R., Kashani, A., Barrow, R., Huganir, R., Ghosh, A., & Snyder, S. (2005) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0409723102 · Cited by 214 · see citing works
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213 · see citing works
Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1 R, 4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)
Fell, M. J., Svensson, K. A., Johnson, B. G., & Schoepp, D. D. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136861 · Cited by 204 · see citing works
Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia
Reynolds, G. P., Czudek, C., & Andrews, H. B. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90039-5 · Cited by 201 · see citing works
Support for involvement of neuregulin 1 in schizophrenia pathophysiology
Petryshen, T. L., Middleton, F. A., Kirby, A. W., Aldinger, K. A., Purcell, S., Tahl, A. R., Morley, C. P., McGann, L., Gentile, K. L., Rockwell, G. N., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001608 · Cited by 195 · see citing works
Phencyclidine and related drugs bind to the activated receptor-channel complex in rat brain membranes
Fagg, G. E. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90719-1 · Cited by 193 · see citing works
Modeling GABA Alterations in Schizophrenia: A Link Between Impaired Inhibition and Altered Gamma and Beta Range Auditory Entrainment
Vierling-Claassen, D., Siekmeier, P. J., Stufflebeam, S. M., & Kopell, N. (2008) · Journal of Neurophysiology · doi:10.1152/jn.00870.2007 · Cited by 191 · see citing works
Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia
Evans, J. D. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.011 · Cited by 191 · see citing works
Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia
Madeira, C., Freitas, M. E., Vargas-Lopes, C., Wolosker, H., & Panizzutti, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.002 · Cited by 190 · see citing works
Epidemiology and Etiology
Roos, A. J. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-36229-3_2 · Cited by 189 · see citing works
Type III Neuregulin-1 Is Required for Normal Sensorimotor Gating, Memory-Related Behaviors, and Corticostriatal Circuit Components
Chen, Y.-J. J., Johnson, M. A., Lieberman, M. D., Goodchild, R. E., Schobel, S., Lewandowski, N., Rosoklija, G., Liu, R.-C., Gingrich, J. A., Small, S., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1815-08.2008 · Cited by 188 · see citing works
Expression of NMDAR1, GluR1, GluR7, and KA1 Glutamate Receptor mRNAs Is Decreased in Frontal Cortex of “Neuroleptic‐Free” Schizophrenics: Evidence on Reversible Up‐Regulation by Typical Neuroleptics
Sokolov, B. P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062454.x · Cited by 186 · see citing works
The Relationship of Structural Alterations to Cognitive Deficits in Schizophrenia: A Voxel-Based Morphometry Study
Antonova, E., Kumari, V., Morris, R. G., Halari, R., Anilkumar, A. P., Mehrotra, R., & Sharma, T. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.036 · Cited by 178 · see citing works
Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function inNRG1+/−Knock-Outs Compared with Wild-Type Mice
Bjarnadóttir, M., Misner, D., Haverfield-Gross, S., Bruun, S., Helgason, V. G., Stefánsson, H., Sigmundsson, A., Firth, D. R., Nielsen, B., Stefansdottir, R., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4314-06.2007 · Cited by 176 · see citing works
Genetic variation in DTNBP1 influences general cognitive ability
Burdick, K. E., Lencz, T., Funke, B., Finn, C. T., Szeszko, P. R., Kane, J. M., Kucherlapati, R., & Malhotra, A. K. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi481 · Cited by 173 · see citing works
Composition of the Synaptic PSD-95 Complex
Döṣemeci, A., Makusky, A. J., Jankowska‐Stephens, E., Yang, X., Slotta, D. J., & Markey, S. P. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700040-mcp200 · Cited by 172 · see citing works
Dopamine receptors, neuroleptics, and schizophrenia
Snyder, S. H. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.4.460 · Cited by 169 · see citing works
DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling
Wilson, G. M., Flibotte, S., Chopra, V. S., Melnyk, B. L., Honer, W. G., & Holt, R. A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi489 · Cited by 167 · see citing works
Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association With Schizophrenia Endophenotypes
Wonodi, I., Stine, O. C., Sathyasaikumar, K. V., Roberts, R. C., Mitchell, B. D., Hong, L. E., Kajii, Y., Thaker, G. K., & Schwarcz, R. M. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.71 · Cited by 166 · see citing works
Long‐term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism
Harris, L. W., Sharp, T., Gartlon, J. E., Jones, D. N. C., & Harrison, P. J. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02902.x · Cited by 162 · see citing works
Postnatal Phencyclidine Administration Selectively Reduces Adult Cortical Parvalbumin-Containing Interneurons
Wang, C. Z., Yang, S. F., Xia, Y., & Johnson, K. M. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301647 · Cited by 161 · see citing works
Genetic associations with schizophrenia: Meta-analyses of 12 candidate genes
Shi, J., Gershon, E. S., & Liu, C. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.06.016 · Cited by 159 · see citing works
Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia
Porter, R. H. P., Eastwood, S. L., & Harrison, P. J. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01404-7 · Cited by 158 · see citing works
Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia
Stefani, M. R., & Moghaddam, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.031 · Cited by 157 · see citing works
Modelling prefrontal cortex deficits in schizophrenia: implications for treatment
Pratt, J. A., Winchester, C. L., Egerton, A., Cochran, S., & Morris, B. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.24 · Cited by 153 · see citing works
Calcium binding protein markers of GABA deficits in schizophrenia — post mortem studies and animal models
Reynolds, G. P., Abdul-Monim, Z., Neill, J. C., & Zhang, Z. (2004) · Neurotoxicity Research · doi:10.1007/bf03033297 · Cited by 150 · see citing works
Effect of Phencyclidine in Chronic Schizophrenics
Itil, T. M., Keskiner, A., Kiremitci, N., & Holden, J. (1967) · Canadian Psychiatric Association Journal · doi:10.1177/070674376701200217 · Cited by 148 · see citing works
Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview
Kane, J. M. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296918 · Cited by 147 · see citing works
pLG72 Modulates Intracellular D-Serine Levels through Its Interaction with D-Amino Acid Oxidase
Sacchi, S., Bernasconi, M., Martineau, M., Mothet, J., Ruzzene, M., Pilone, M. S., Pollegioni, L., & Molla, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709153200 · Cited by 146 · see citing works
Neuroimaging of cognitive disability in schizophrenia: Search for a pathophysiological mechanism
Ragland, J. D., Yoon, J. H., Minzenberg, M., & Carter, C. S. (2007) · International Review of Psychiatry · doi:10.1080/09540260701486365 · Cited by 146 · see citing works
[3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics
Hanada, S., Mita, T., Nishino, N., & Tanaka, C. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90341-9 · Cited by 140 · see citing works
Critical Appraisal of DNA Microarrays in Psychiatric Genomics
Mirnics, K., Levitt, P. R., & Lewis, D. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.003 · Cited by 138 · see citing works
Serine racemase binds to PICK1: potential relevance to schizophrenia
Fujii, K., Maeda, K., Hikida, T., Mustafa, A., Balkissoon, R., Xia, J., Yamada, T., Ozeki, Y., Kawahara, R., Okawa, M., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001776 · Cited by 137 · see citing works
NMDA Receptor Antagonists Disinhibit Rat Posterior Cingulate and Retrosplenial Cortices: A Potential Mechanism of Neurotoxicity
Li, Q., Clark, S., Lewis, D. V., & Wilson, W. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03070.2002 · Cited by 132 · see citing works
NR2B Signaling Regulates the Development of Synaptic AMPA Receptor Current
Hall, B. J., Ripley, B. A., & Ghosh, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3793-07.2007 · Cited by 130 · see citing works
Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina
Yazulla, S., Studholme, K. M., McIntosh, H. H., & Deutsch, D. G. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19991206)415:1 · Cited by 128 · see citing works
Self-citation
Spatial Memory Deficits Induced by Perinatal Treatment of Rats with PCP and Reversal Effect of D-Serine
Andersen, J. D., & Pouzet, B. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300394 · Cited by 126 · see citing works
Ionotropic Glutamate Receptors as Therapeutic Targets in Schizophrenia
Coyle, J. T., Tsai, G. E., & GOFF, D. C. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606212 · Cited by 126 · see citing works
Self-citation
The influence of agonal status on some neurochemical activities of postmortem human brain tissue
Perry, E. K., Perry, R. H., & Tomlinson, B. E. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90334-2 · Cited by 125 · see citing works
No deficit in total number of neurons in the prefrontal cortex in schizophrenics
Thune, J. J., Uylings, H. B. M., & Pakkenberg, B. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00043-1 · Cited by 124 · see citing works
Sites of antagonist action on N-methyl-D-aspartic acid receptors studied using fluctuation analysis and a rapid perfusion technique
Mayer, M. L., Westbrook, G. L., & Vyklický, L. (1988) · Journal of Neurophysiology · doi:10.1152/jn.1988.60.2.645 · Cited by 123 · see citing works
Selective reduction of a PDZ protein, SAP‐97, in the prefrontal cortex of patients with chronic schizophrenia
Toyooka, K., Iritani, S., Makifuchi, T., Shirakawa, O., Kitamura, N., Maeda, K., Nakamura, R., Niizato, K., Watanabe, M., Kakita, A., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01181.x · Cited by 121 · see citing works
Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients
Hazlett, E. A., Buchsbaum, M. S., Haznedar, M. M., Newmark, R. E., Goldstein, K. E., Zelmanova, Y., Glanton, C. F., Torosjan, Y., New, A. S., Lo, J. N., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.472 · Cited by 120 · see citing works
Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats
Abekawa, T., Ito, K., Nakagawa, S., & Koyama, T. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0729-8 · Cited by 118 · see citing works
Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects
Spokes, E. G., Garrett, N., Rossor, M. N., & Iversen, L. L. (1980) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(80)90103-3 · Cited by 117 · see citing works
Activation of Medial Prefrontal Cortex by Phencyclidine is Mediated via a Hippocampo-prefrontal Pathway
Jodo, E., Suzuki, Y., Katayama, T., Hoshino, K.-Y., Takeuchi, S., Niwa, S., & Kayama, Y. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh168 · Cited by 116 · see citing works
Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder
Pickard, B. S., Malloy, M. P., Christoforou, A., Thomson, P. A., Evans, K. L., Morris, S. W., Hampson, M. E., Porteous, D. J., Blackwood, D., & Muir, W. J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001867 · Cited by 114 · see citing works
A Genetic Variant of the Serine Racemase Gene Is Associated with Schizophrenia
Morita, Y., Ujike, H., Tanaka, Y., Otani, K., Kishimoto, M., Morio, A., Kotaka, T., Okahisa, Y., Matsushita, M., Morikawa, A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.025 · Cited by 112 · see citing works
Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia
Ohnuma, T., Kato, H., Arai, H., Faull, R. L. M., McKenna, P. J., & Emson, P. C. (2000) · Neuroreport · doi:10.1097/00001756-200009280-00019 · Cited by 111 · see citing works
Dendritic spines shaped by synaptic activity
Segal, M., & Andersen, P. N. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00123-9 · Cited by 107 · see citing works
Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex
Zhang, Y., Behrens, M. M., & Lisman, J. E. (2008) · Journal of Neurophysiology · doi:10.1152/jn.00079.2008 · Cited by 107 · see citing works
Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression
Kristiansen, L. V., & Meador‐Woodruff, J. H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.012 · Cited by 106 · see citing works
Deciphering the Disease Process of Schizophrenia: The Contribution of Cortical Gaba Neurons
Lewis, D. A., & Hashimoto, T. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78004-7 · Cited by 105 · see citing works
Pyramidal cell size reduction in schizophrenia: evidence for involvement of auditory feedforward circuits
Sweet, R. A., Bergen, S. E., Sun, Z., Sampson, A. R., Pierri, J. N., & Lewis, D. A. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.002 · Cited by 102 · see citing works
Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia
Tkachev, D., Mimmack, M. L., Huffaker, S. J., Ryan, M., & Bahn, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007334 · Cited by 101 · see citing works
D-Amino acid oxidase activity and expression are increased in schizophrenia
Burnet, P. W. J., Eastwood, S. L., Bristow, G. C., Godlewska, B. R., Sikka, P., Walker, M. A., & Harrison, P. J. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.47 · Cited by 101 · see citing works
Is the Dysbindin Gene (DTNBP1) a Susceptibility Gene for Schizophrenia?
Williams, N. M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi061 · Cited by 100 · see citing works
A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia
Mitelman, S. A., Brickman, A. M., Shihabuddin, L., Newmark, R. E., Hazlett, E. A., Haznedar, M. M., & Buchsbaum, M. S. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.04.070 · Cited by 99 · see citing works
The NMDA receptor co-agonists, d-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex
Balu, D. T., Basu, A. C., Corradi, J., Cacace, A. M., & Coyle, J. T. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.006 · Cited by 99 · see citing works
Self-citation
Allelic association of G72/G30 with schizophrenia and bipolar disorder: A comprehensive meta-analysis
Shi, J., Badner, J. A., Gershon, E. S., & Liu, C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.004 · Cited by 98 · see citing works
Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid
Erhardt, S., & Engberg, G. (2002) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2002.00962.x · Cited by 91 · see citing works
Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels
Sharp, F. R., Butman, M., Koıstınaho, J., Aardalen, K., Näkki, R., Massa, S. M., Swanson, R. A., & Sagar, S. M. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90345-x · Cited by 89 · see citing works
Does Ketamine-Mediated N-methyl-D-aspartate Receptor Antagonism Cause Schizophrenia-like Oculomotor Abnormalities?
Radant, A. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00030-x · Cited by 89 · see citing works
Expression of the NR2B‐NMDA receptor subunit and its Tbr‐1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia
Kristiansen, L. V., Patel, S. A., Haroutunian, V. H., & Meador‐Woodruff, J. H. (2010) · Synapse · doi:10.1002/syn.20754 · Cited by 86 · see citing works
Dysbindin (DTNBP1, 6p22.3) is Associated with Childhood-Onset Psychosis and Endophenotypes Measured by the Premorbid Adjustment Scale (PAS)
Gornick, M. C., Addington, A. M., Sporn, A. L., Gogtay, N., GREENSTEIN, D. K., Lenane, M., Gochman, P., Ordóñez, A. E., Balkissoon, R., Vakkalanka, R., et al. (2005) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-005-0028-3 · Cited by 85 · see citing works
Postnatal phencyclidine‐induced deficit in adult water maze performance is associated with N‐methyl‐ d ‐aspartate receptor upregulation
Sircar, R. (2003) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(03)00026-1 · Cited by 80 · see citing works
GluR<sub>5,6,7</sub> subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives
Benes, F. M., Todtenkopf, M. S., & Kostoulakos, P. (2001) · Hippocampus · doi:10.1002/hipo.1065 · Cited by 79 · see citing works
Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: A HuGE review and meta-analysis
Li, D., & He, L. (2007) · Genetics in Medicine · doi:10.1097/01.gim.0000250507.96760.4b · Cited by 79 · see citing works
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Coyle, J. T., Balu, D. T., Benneyworth, M. A., Basu, A. C., & Roseman, A. S. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jcoyle · Cited by 75 · see citing works
Self-citation
Kynurenic Acid And Schizophrenia
Erhardt, S., Schwieler, L., & Engberg, G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0135-0_18 · Cited by 74 · see citing works
Preliminary evidence for a link between schizophrenia and NMDA–glycine site receptor ligand metabolic enzymes, d -amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1)
Kapoor, R., Lim, K. S., Cheng, A., Garrick, T. M., & Kapoor, V. (2006) · Brain Research · doi:10.1016/j.brainres.2006.05.082 · Cited by 73 · see citing works
Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia
Begni, S., Popoli, M., Moraschi, S., Bignotti, S., Tura, G. B., & Gennarelli, M. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000987 · Cited by 71 · see citing works
Dr. Snyder Replies
Snyder, S. H. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.7.992 · Cited by 69 · see citing works
Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR
Fricker, A.-C., Mok, M. H. S., de la Flor, R., Shah, A. J., Woolley, M. L., Dawson, L. A., & Kew, J. N. C. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.03.002 · Cited by 68 · see citing works
Cortical Glutamatergic Markers in Schizophrenia
Scarr, E., Beneyto, M., Meador‐Woodruff, J. H., & Dean, B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300758 · Cited by 67 · see citing works
NAAG Reduces NMDA Receptor Current in CA1 Hippocampal Pyramidal Neurons of Acute Slices and Dissociated Neurons
Bergeron, R., Coyle, J. T., Tsai, G., & Greene, R. W. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300559 · Cited by 64 · see citing works
Self-citation
Subnuclear localization of FOS‐like immunoreactivity in the parabrachial nucleus after orofacial nociceptive stimulation of the awake rat
Hermanson, O., & Blomqvist, A. (1997) · The Journal of comparative neurology · doi:10.1002/(sici)1096-9861(19971013)387:1 · Cited by 61 · see citing works
Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia
Huerta, I., McCullumsmith, R. E., Haroutunian, V. H., Giménez‐Amaya, J. M., & Meador‐Woodruff, J. H. (2006) · Synapse · doi:10.1002/syn.20250 · Cited by 60 · see citing works
Evidence for association and epistasis at the DAOA/G30 and D ‐amino acid oxidase loci in an Irish schizophrenia sample
Corvin, A. P., McGhee, K. A., Murphy, K., Donohoe, G. J., Nangle, J. M., Schwaiger, S., KENNY, N. W., Clarke, S., Meagher, D. J., Quinn, J. P., et al. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30452 · Cited by 59 · see citing works
Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder
Woo, T.-U. W., SHRESTHA, K., AMSTRONG, C., Minns, M., WALSH, J., & Benes, F. M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.023 · Cited by 58 · see citing works
Association of DAAO with schizophrenia in the Chinese population
Liu, X., He, G., Wang, X., Chen, Q., Qian, X., Lin, W., Li, D., Gu, N., Feng, G., & He, L. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.07.078 · Cited by 53 · see citing works
Polymorphism in the 5′-promoter region of serine racemase gene in schizophrenia
Goltsov, A. Y., Loseva, J. G., Андреева, Т. В., Grigorenko, A. P., Abramova, L. I., Каледа, В. Г., Александровна, О. В., Moliaka, Y. K., & Rogaev, E. I. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001801 · Cited by 50 · see citing works

Flagged first, then by citations

Sorted by citations

The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue
Brisch, R., Saniotis, A., Wolf, R. J., Bielau, H., Bernstein, H., Steiner, J. H., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 520 · see citing works
The touchscreen operant platform for testing learning and memory in rats and mice
Horner, A. E., Heath, C. J., Hvoslef‐Eide, M., Kent, B. A., Kim, C. H., Nilsson, S. R. O., Alsiö, J., Oomen, C. A., Holmes, A., Saksida, L. M., et al. (2013) · Nature Protocols · doi:10.1038/nprot.2013.122 · Cited by 412 · see citing works
Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Millan, M. J., Fone, K. C. F., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 354 · see citing works
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304 · see citing works
Reviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303 · see citing works
Microglial Dysregulation in Psychiatric Disease
Frick, L. R., Williams, K., & Pittenger, C. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/608654 · Cited by 299 · see citing works
Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology?
Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262 · see citing works
Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction
Balu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., Bolshakov, V. Y., & Coyle, J. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304308110 · Cited by 217 · see citing works
Self-citation
Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents
Bubser, M., Bridges, T. M., Dencker, D., Gould, R. W., Grannan, M. D., Noetzel, M. J., Lamsal, A., Niswender, C. M., Daniels, J. S., Poslusney, M. S., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500128b · Cited by 155 · see citing works
Major channels involved in neuropsychiatric disorders and therapeutic perspectives
Imbrici, P., Camerino, D. C., & Tricarico, D. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00076 · Cited by 148 · see citing works
Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia
Chung, D. W., Fish, K. N., & Lewis, D. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010025 · Cited by 148 · see citing works
“Lower glutamatergic drive to PV interneurons has been hypothesized to be the cause of deficient PV interneuron activity in schizophrenia(6-8).”
Background
From “Special <scp>K</scp>” to “Special <scp>M</scp>”: The Evolution of the Recreational Use of Ketamine and Methoxetamine
Corazza, O., Assi, S., & Schifano, F. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12063 · Cited by 146 · see citing works
Biased mGlu 5 -Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents
Rook, J. M., Xiang, Z., Lv, X., Ghoshal, A., Dickerson, J. W., Bridges, T. M., Johnson, K. A., Foster, D. J., Gregory, K. J., Vinson, P. N., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.063 · Cited by 130 · see citing works
Ketamine applications beyond anesthesia – A literature review
Nowacka, A., & Borczyk, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172547 · Cited by 129 · see citing works
Glutamatergic Postsynaptic Density Protein Dysfunctions in Synaptic Plasticity and Dendritic Spines Morphology: Relevance to Schizophrenia and Other Behavioral Disorders Pathophysiology, and Implications for Novel Therapeutic Approaches
de Bartolomeis, A., Latte, G., Tomasetti, C., & Iasevoli, F. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8534-3 · Cited by 126 · see citing works
In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders
Pantazopoulos, H., & Berretta, S. (2015) · Neural Plasticity · doi:10.1155/2016/9847696 · Cited by 118 · see citing works
Obsessive-Compulsive Disorder as a Risk Factor for Schizophrenia
Meier, S. M., Petersen, L. V., Pedersen, M. G., Arendt, M. C. B. B., Nielsen, P. R., Mattheisen, M., Mors, O. N., & Mortensen, P. B. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1011 · Cited by 115 · see citing works
Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia
Meltzer, H. Y., Rajagopal, L., Huang, M., Oyamada, Y., Kwon, S., & Horiguchi, M. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000928 · Cited by 114 · see citing works
Trans-synaptic zinc mobilization improves social interaction in two mouse models of autism through NMDAR activation
Lee, E., Lee, H., Huang, T., Chung, C., Shin, W., Kim, K., Koh, J., Hsueh, Y., & Kim, E. (2015) · Nature Communications · doi:10.1038/ncomms8168 · Cited by 107 · see citing works
IRSp53/BAIAP2 in dendritic spine development, NMDA receptor regulation, and psychiatric disorders
Kang, J., Park, H., & Kim, E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.019 · Cited by 98 · see citing works
NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms
Snyder, M. A., & Gao, W. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.03.010 · Cited by 93 · see citing works
Ketogenic diet as a metabolic treatment for mental illness
Norwitz, N. G., Sethi, S., & Palmer, C. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000564 · Cited by 87 · see citing works
Targeting muscarinic receptors to treat schizophrenia
Foster, D. J., Bryant, Z., & Conn, P. J. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113201 · Cited by 87 · see citing works
Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia
Khadimallah, I., Jenni, R., Cabungcal, J.-H., Cleusix, M., Fournier, M., Béard, E., Klauser, P., Knebel, J., Murray, M. M., Retsa, C., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01313-9 · Cited by 88 · see citing works
Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic Implications
Willard, S. S., & Koochekpour, S. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.6475 · Cited by 86 · see citing works
Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia
Groß, G., Wicke, K. M., & Drescher, K. U. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0806-3 · Cited by 86 · see citing works
Conceptualization and treatment of negative symptoms in schizophrenia
Sarkar, S. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i4.352 · Cited by 88 · see citing works
Effects of prefrontal cortex and hippocampal NMDA NR1-subunit deletion on complex cognitive and social behaviors
Finlay, J. M., Dunham, G. A., Isherwood, A. M., Newton, C. J., Nguyen, T. V., Reppar, P. C., Snitkovski, I., Paschall, S. A., & Greene, R. W. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.037 · Cited by 78 · see citing works
Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5‐ HT )2A and DA D2 antagonism and 5‐ HT 1A partial agonism
Huang, M., Panos, J., Kwon, S., Oyamada, Y., Rajagopal, L., & Meltzer, H. Y. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12512 · Cited by 73 · see citing works
Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis
de Bartolomeis, A., Sarappa, C., Buonaguro, E. F., Marmo, F., Eramo, A., Tomasetti, C., & Iasevoli, F. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.010 · Cited by 72 · see citing works
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
Heffernan, M. L. R., Herman, L. W., Brown, S. P., JONES, P. G., Shao, L., Hewitt, M. C., Campbell, J. E., Dedic, N., Hopkins, S. C., Koblan, K. S., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00527 · Cited by 71 · see citing works
Ketogenic diet reverses behavioral abnormalities in an acute NMDA receptor hypofunction model of schizophrenia
Kraeuter, A.-K., Loxton, H., Lima, B. C., Rudd, D., & Sarnyai, Z. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.10.041 · Cited by 69 · see citing works
Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A 1H MRS study
Hugdahl, K., Craven, A. R., Nygård, M., Løberg, E.-M., Berle, J. Ø., Johnsen, E., Kroken, R., Specht, K., Andreassen, O. A., & Ersland, L. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.015 · Cited by 64 · see citing works
Sex Differences of Microglia and Synapses in the Hippocampal Dentate Gyrus of Adult Mouse Offspring Exposed to Maternal Immune Activation
Hui, C. W., Vecchiarelli, H. A., Gervais, É., Luo, X., Michaud, F., Scheefhals, L., Bisht, K., Sharma, K., Topolnik, L., & Tremblay, M.-È. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.558181 · Cited by 64 · see citing works
Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse
Misiak, B., Frydecka, D., Ślężak, R., Piotrowski, P., & Kiejna, A. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9534-3 · Cited by 62 · see citing works
Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice
Gould, R. W., Dencker, D., Grannan, M. D., Bubser, M., Zhan, X., Wess, J., Xiang, Z., Locuson, C. W., Lindsley, C. W., Conn, P. J., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00123 · Cited by 60 · see citing works
Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs
Muguruza, C., Meana, J. J., & Callado, L. F. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00130 · Cited by 61 · see citing works
Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: Implications for neuropsychiatric diseases
Lin, H., Hsu, F., Baumann, B. H., Coulter, D. A., & Lynch, D. R. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.11.021 · Cited by 60 · see citing works
Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia
Falkenberg, L. E., Westerhausen, R., Craven, A. R., Johnsen, E., Kroken, R. A., L⊘berg, E.-M., Specht, K., & Hugdahl, K. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.03.014 · Cited by 59 · see citing works
Effects of beta-hydroxybutyrate administration on MK-801-induced schizophrenia-like behaviour in mice
Kraeuter, A.-K., Mashavave, T., Suvarna, A., van den Buuse, M., & Sarnyai, Z. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05467-2 · Cited by 59 · see citing works
Animal models for predicting the efficacy and side effects of antipsychotic drugs.
Gobira, P., Ropke, J., Aguiar, D., Crippa, J., & Moreira, F. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-1164 · Cited by 56 · see citing works
Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders
Yan, L.-Q., Shamir, A., Skirzewski, M., Leiva‐Salcedo, E., Kwon, O., Karavanova, I. D., Paredes, D., Malkesman, O., Bailey, K. R., Vullhorst, D., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.22 · Cited by 57 · see citing works
The Role of Serine Racemase in the Pathophysiology of Brain Disorders
Coyle, J., & Balu, D. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.10.002 · Cited by 48 · see citing works
Self-citation
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154
Gould, R. W., Grannan, M. D., Gunter, B. W., Ball, J., Bubser, M., Bridges, T. M., Wess, J., Wood, M. W., Brandon, N. J., Duggan, M. E., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.013 · Cited by 54 · see citing works
Holding Multiple Items in Short Term Memory: A Neural Mechanism
Rolls, E. T., Dempere‐Marco, L., & Deco, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061078 · Cited by 53 · see citing works
Novel Antischizophrenia Treatments
Geyer, M. A., & Groß, G. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2 · Cited by 55 · see citing works
Schizophrenia
Leucht, S., Siafis, S., McGrath, J. J., McGorry, P. D., Howes, O. D., Tamminga, C. A., Carr, R., Bighelli, I., Schneider‐Thoma, J., Priller, J., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00667-6 · Cited by 63 · see citing works
Magnetic Resonance Imaging in Studying Schizophrenia, Negative Symptoms, and the Glutamate System
Gruber, O., Chadha, A. S., & Aach, H. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00032 · Cited by 54 · see citing works
Mapping pathologic circuitry in schizophrenia
Glausier, J. R., & Lewis, D. A. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63639-3.00025-6 · Cited by 52 · see citing works
The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment
Iasevoli, F., Tomasetti, C., Buonaguro, E. F., & de Bartolomeis, A. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140324183406 · Cited by 53 · see citing works
Anterior Cingulate Glutamate and GABA Associations on Functional Connectivity in Schizophrenia
Shukla, D. K., Wijtenburg, S. A., Chen, H., Chiappelli, J., Kochunov, P., Hong, L. E., & Rowland, L. M. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby075 · Cited by 52 · see citing works
Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators
Yohn, S. E., Foster, D. J., Covey, D. P., Moehle, M. S., Galbraith, J., García-Barrantes, P. M., Cho, H. P., Bubser, M., Blobaum, A. L., Joffe, M. E., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0206-2 · Cited by 52 · see citing works
Ketogenic diet for schizophrenia
Sarnyai, Z., Kraeuter, A.-K., & Palmer, C. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000535 · Cited by 52 · see citing works
Impact of structural aberrancy of polysialic acid and its synthetic enzyme ST8SIA2 in schizophrenia
Sato, C., & Kitajima, K. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00061 · Cited by 51 · see citing works
Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach
Grados, M. A., Specht, M. W., Sung, H.-M., & Fortune, D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.845553 · Cited by 49 · see citing works
Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019
Corkery, J., Hung, W.-C., Claridge, H., Goodair, C., Copeland, C. S., & Schifano, F. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211021588 · Cited by 48 · see citing works
Social neuroscience in psychiatry: unravelling the neural mechanisms of social dysfunction
Fett, A.-K. J., Shergill, S. S., & Krabbendam, L. (2014) · Psychological Medicine · doi:10.1017/s0033291714002487 · Cited by 48 · see citing works
Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators
Yao, L., & Zhou, Q. (2017) · Neural Plasticity · doi:10.1155/2017/2875904 · Cited by 48 · see citing works
Serotonin and Glutamate Interactions in Preclinical Schizophrenia Models
Shah, U. H., & González-Maeso, J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00044 · Cited by 44 · see citing works
Design, Synthesis, and Structure–Activity Relationship of a Novel Series of GluN2C-Selective Potentiators
Zimmerman, S. S., Khatri, A., Garnier‐Amblard, E. C., Mullasseril, P., Kurtkaya, N. L., Gyoneva, S., Hansen, K. B., Traynelis, S. F., & Liotta, D. C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401695d · Cited by 47 · see citing works
Environmental enrichment or selective activation of parvalbumin-expressing interneurons ameliorates synaptic and behavioral deficits in animal models with schizophrenia-like behaviors during adolescence
Huang, Y., Jiang, H., Zheng, Q., Fok, A. H. K., Li, X., Lau, C. G., & Lai, C. S. W. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-01005-w · Cited by 47 · see citing works
Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders
Johnson, C. R., Kangas, B. D., Jutkiewicz, E. M., Bergman, J., & Coop, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020398 · Cited by 45 · see citing works
Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Kreinin, A., Bawakny, N., & Ritsner, M. S. (2014) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.krba.013114 · Cited by 44 · see citing works
Investigating the neurobiology of schizophrenia and other major psychiatric disorders with Transcranial Magnetic Stimulation
Kaskie, R. E., & Ferrarelli, F. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.045 · Cited by 43 · see citing works
Higher ambient synaptic glutamate at inhibitory versus excitatory neurons differentially impacts NMDA receptor activity
Yao, L., Grand, T., Hanson, J. E., Paoletti, P., & Zhou, Q. (2018) · Nature Communications · doi:10.1038/s41467-018-06512-7 · Cited by 43 · see citing works
A lack of GluN2A-containing NMDA receptors confers a vulnerability to redox dysregulation: Consequences on parvalbumin interneurons, and their perineuronal nets
Cardis, R., Cabungcal, J.-H., Dwir, D., Kim, Q., & Steullet, P. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.10.006 · Cited by 42 · see citing works
Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment
Huang, X., & Song, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21512 · Cited by 41 · see citing works
A selective review of glutamate pharmacological therapy in obsessive–compulsive and related disorders
Grados, M. A., Atkins, E., Kovacikova, G. I., & McVicar, E. L. (2015) · Psychology Research and Behavior Management · doi:10.2147/prbm.s58601 · Cited by 39 · see citing works
The three-dimensional landscape of the genome in human brain tissue unveils regulatory mechanisms leading to schizophrenia risk
Mah, W., & Won, H. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.03.007 · Cited by 38 · see citing works
Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus
Nomura, T., Oyamada, Y., Fernandes, H. B., Remmers, C. L., Xu, J., Meltzer, H. Y., & Contractor, A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.012 · Cited by 37 · see citing works
Weaving a Net of Neurobiological Mechanisms in Schizophrenia and Unraveling the Underlying Pathophysiology
Bitanihirwe, B. K. Y., Mauney, S. A., & Woo, T.-U. W. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.1047 · Cited by 37 · see citing works
Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia
Bristow, G. C., Bostrom, J., Haroutunian, V. H., & Sodhi, M. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.025 · Cited by 36 · see citing works
Computational Neuropsychiatry – Schizophrenia as a Cognitive Brain Network Disorder
Dauvermann, M. R., Whalley, H. C., Schmidt, A., Lee, G. L., Romaniuk, L., Roberts, N., Johnstone, E. C., Lawrie, S. M., & Moorhead, T. W. J. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00030 · Cited by 35 · see citing works
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects
Gould, R. W., Nedelcovych, M. T., Gong, X., Tsai, E., Bubser, M., Bridges, T. M., Wood, M. R., Duggan, M. E., Brandon, N. J., Dunlop, J., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.11.016 · Cited by 35 · see citing works
The Adenosine Neuromodulation System in Schizophrenia
Rial, D., Lara, D. R., & Cunha, R. A. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00016-7 · Cited by 32 · see citing works
Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
Strzelecki, D., Podgórski, M. T., Kałużyńska, O., Gawlik-Kotelnicka, O., Stefańczyk, L., Kotlicka‐Antczak, M., Gmitrowicz, A., & Grzelak, P. (2015) · Nutrients · doi:10.3390/nu7105427 · Cited by 31 · see citing works
Ketogenic Therapy in Serious Mental Illness: Emerging Evidence
Sarnyai, Z., & Palmer, C. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa036 · Cited by 30 · see citing works
Peripheral Glutamate Levels in Schizophrenia: Evidence from a Meta-Analysis
Song, J., Viggiano, A., Monda, M., & Luca, V. D. (2014) · Neuropsychobiology · doi:10.1159/000364828 · Cited by 29 · see citing works
d-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia
Cheng, Y., Lin, C., & Lane, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010917 · Cited by 29 · see citing works
Astrocytes as Pharmacological Targets in the Treatment of Schizophrenia
Pocivavsek, A., Notarangelo, F. M., Wu, H., Bruno, J., & Schwarcz, R. (2016) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00025-0 · Cited by 33 · see citing works
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects
Le, T. T., Vincenzo, J. D. D., Teopiz, K. M., Lee, Y. L., Cha, D. S., Lui, L. M. W., Rodrigues, N. B., Ho, R., Cao, B., Lin, K., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114231 · Cited by 27 · see citing works
Multiple functions of neuronal plasma membrane neurotransmitter transporters
Raiteri, L., & Raiteri, M. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.08.002 · Cited by 27 · see citing works
The interplay between glutamatergic circuits and oxytocin neurons in the hypothalamus and its relevance to neurodevelopmental disorders
Leithead, A. B., Tasker, J. G., & Harony‐Nicolas, H. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13061 · Cited by 26 · see citing works
Maternal immune activation alters glutamic acid decarboxylase-67 expression in the brains of adult rat offspring
Cassella, S. N., Hemmerle, A. M., Lundgren, K. H., Kyser, T. L., Ahlbrand, R. A., Bronson, S. L., Richtand, N. M., & Seroogy, K. B. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.041 · Cited by 26 · see citing works
Altered functional connectivity links in neuroleptic-naïve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition
Pu, W., Rolls, E. T., Guo, S., Liu, H., Yu, Y., Xue, Z., Feng, J., & Liu, Z. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.10.004 · Cited by 26 · see citing works
mGlu5 Positive Allosteric Modulators Facilitate Long-Term Potentiation via Disinhibition Mediated by mGlu5-Endocannabinoid Signaling
Xiang, Z., Lv, X., Maksymetz, J., Stansley, B. J., Ghoshal, A., Gogliotti, R. G., Niswender, C. M., Lindsley, C. W., & Conn, P. J. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00017 · Cited by 25 · see citing works
How do zebrafish ( Danio rerio ) respond to MK‐801 and amphetamine? Relevance for assessing schizophrenia‐related endophenotypes in alternative model organisms
Benvenutti, R., Gallas‐Lopes, M., Sachett, A., Marcon, M., Strogulski, N. R., Reis, C. G., Chitolina, R., Piato, Â., & Herrmann, A. P. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24948 · Cited by 21 · see citing works
A Novel Aminotetralin-Type Serotonin (5-HT) 2C Receptor-Specific Agonist and 5-HT2A Competitive Antagonist/5-HT2B Inverse Agonist with Preclinical Efficacy for Psychoses
Canal, C. E., Morgan, D., Felsing, D. E., Kondabolu, K., Rowland, N. E., Robertson, K. L., Sakhuja, R., & Booth, R. G. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212373 · Cited by 23 · see citing works
Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress
Amin, H. S., Parikh, P. K., & Ghate, M. D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113155 · Cited by 22 · see citing works
Ketamine's schizophrenia-like effects are prevented by targeting PTP1B
Qin, Z., Zhang, L., ZASLOFF, M. A., Stewart, A. F. R., & Chen, H. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105397 · Cited by 24 · see citing works
Phosphoserine phosphatase activity is elevated and correlates negatively with plasma d-serine concentration in patients with schizophrenia
Ozeki, Y., Sekine, M., Fujii, K., Watanabe, T., Okayasu, H., Takano, Y., Shinozaki, T., Aoki, A., Akiyama, K., Homma, H., et al. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.010 · Cited by 21 · see citing works
Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction
Rajagopal, L., Soni, D., & Meltzer, H. Y. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.005 · Cited by 21 · see citing works
Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases
Coughlin, Q., Hopper, A. T., Blanco, M.-J., Tirunagaru, V. G., Robichaud, A. J., & Doller, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01651 · Cited by 21 · see citing works
Structure–Activity Relationship Study of Ionotropic Glutamate Receptor Antagonist (2S,3R)-3-(3-Carboxyphenyl)pyrrolidine-2-carboxylic Acid
Krogsgaard‐Larsen, N., Storgaard, M., Møller, C. T., Demmer, C. S., Hansen, J. K., Han, L., Monrad, R. N., Nielsen, B., Tapken, D., Pickering, D. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00750 · Cited by 19 · see citing works
A novel liquid chromatography/tandem mass spectrometry method for the quantification of glycine as biomarker in brain microdialysis and cerebrospinal fluid samples within 5min
Voehringer, P., Fuertig, R., & Ferger, B. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.09.011 · Cited by 18 · see citing works
Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG
Holter, K. M., Lekander, A., LaValley, C. M., Bedingham, E. G., Pierce, B. E., Sands, L. P., Lindsley, C. W., Jones, C. K., & Gould, R. W. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.700822 · Cited by 17 · see citing works
Characterization of the novel GlyT1 PET tracer [18F]MK‐6577 in humans
Joshi, A. D., Bohorquez, S. M. S., Bormans, G. M., Koole, M. J. B., Hoon, J. N. J. M. D., Hecken, A. V., Depré, M., Lepeleire, I. D., Laere, K. V., Sur, C., et al. (2014) · Synapse · doi:10.1002/syn.21782 · Cited by 17 · see citing works
Pedophilic sex offenders are characterised by reduced GABA concentration in dorsal anterior cingulate cortex
Ristow, I., Li, M., Čolić, L., Marr, V., Födisch, C., von Düring, F., Schiltz, K., Drumkova, K., Witzel, J. G., Walter, H., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.01.018 · Cited by 17 · see citing works
Protective effect of N-acetylcysteine on MK-801-induced testicular oxidative stress in mice
Türkmen, R., AKOSMAN, M. S., & Demirel, H. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.139 · Cited by 17 · see citing works
A role for endothelial NMDA receptors in the pathophysiology of schizophrenia
Intson, K., Geissah, S., McCullumsmith, R. E., & Ramsey, A. J. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.10.004 · Cited by 16 · see citing works

Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577 · see citing works
Self-citation
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
GOFF, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 914 · see citing works
Self-citation
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · see citing works
Self-citation
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · see citing works
Self-citation
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530 · see citing works

Authors: Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G.
Affiliations: Harvard University (US)
Corresponding author: Coyle, Joseph T.
ORCID: Coyle, Joseph T.
Benneyworth, Michael
Balu, Darrick
Venue: Handbook of Experimental Pharmacology
Publisher: Springer Berlin Heidelberg
Published: 2012
Issue: 213
Pages: 267-295
ISSN: 0171-2004 (ISSN-L)
1865-0325
DOI: 10.1007/978-3-642-25758-2_10
PMC: PMC4817347
OpenAlex: W1872072116
Cited by: 180
References: 216
Citations by year: 2026: 7 · 2025: 7 · 2024: 6 · 2023: 4 · 2022: 13 · 2021: 19 · 2020: 10 · 2019: 9 · 2018: 10 · 2017: 11 · 2016: 11 · 2015: 21 · 2014: 25 · 2013: 22 · 2012: 4
FWCI: 81.63
Type: book chapter
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Handbook of experimental pharmacology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Public Health Service
National Institute of Mental Health (P50MH060450, R01 MH51290, R01MH051290, F32MH090697, P50MH06045)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: schizophrenia, NMDA receptor hypofunction, ketamine, dissociative anesthetics, postsynaptic density, D-amino acid oxidase, G72, dysbindin, neuregulin, parvalbumin interneurons, cognitive impairment, negative symptoms, psychosis, dopamine release, glutamatergic neurotransmission
MeSH terms: Animals, Cognition, gamma-Aminobutyric Acid, Humans, Ketamine, Synaptic Transmission, Schizophrenia, Synapses, Receptors, N-Methyl-D-Aspartate, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks